{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ABT-418", "ABT-594", "analgesics", "epibatidine", "nicotinic acetylcholine receptors"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30583611", "DateCompleted": {"Year": "2019", "Month": "06", "Day": "05"}, "DateRevised": {"Year": "2020", "Month": "03", "Day": "09"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "12", "Day": "23"}], "Language": ["eng"], "ELocationID": ["6", "10.3390/biom9010006"], "Journal": {"ISSN": "2218-273X", "JournalIssue": {"Volume": "9", "Issue": "1", "PubDate": {"Year": "2018", "Month": "Dec", "Day": "23"}}, "Title": "Biomolecules", "ISOAbbreviation": "Biomolecules"}, "ArticleTitle": "Epibatidine: A Promising Natural Alkaloid in Health.", "Abstract": {"AbstractText": ["Epibatidine is a natural alkaloid that acts at nicotinic acetylcholine receptors (nAChRs). The present review aims to carefully discuss the affinity of epibatidine and its synthetic derivatives, analogues to nAChRs for \u03b14\u03b22 subtype, pharmacokinetic parameters, and its role in health. Published literature shows a low affinity and lack of binding of epibatidine and its synthetic analogues to plasma proteins, indicating their availability for metabolism. Because of its high toxicity, the therapeutic use of epibatidine is hampered. However, new synthetic analogs endowed from this molecule have been developed, with a better therapeutic window and improved selectivity. All these aspects are also discussed here. On the other hand, many reports are devoted to structure\u207bactivity relationships to obtain optically active epibatidine and its analogues, and to access its pharmacological effects. Although pharmacological results are obtained from experimental studies and only a few clinical trials, new perspectives are open for the discovery of new drug therapies."]}, "AuthorList": [{"Identifier": ["0000-0002-6900-9797"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, School of Medicine, Bam University of Medical Sciences, Bam 44340847, Iran. bahar.salehi007@gmail.com."}], "LastName": "Salehi", "ForeName": "Bahare", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy. simona.sestito@for.unipi.it."}], "LastName": "Sestito", "ForeName": "Simona", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy. simona.rapposelli@unipi.it."}, {"Identifier": [], "Affiliation": "Interdepartmental Research Centre for Biology and Pathology of Aging, University of Pisa, 55126 Pisa, Italy. simona.rapposelli@unipi.it."}], "LastName": "Rapposelli", "ForeName": "Simona", "Initials": "S"}, {"Identifier": ["0000-0002-6007-6184"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Francesco Marzolo, 5, 35131 Padova (PD), Italy. gregorio.peron@ub.edu."}], "LastName": "Peron", "ForeName": "Gregorio", "Initials": "G"}, {"Identifier": ["0000-0002-1523-9116"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, University of Medicine and Pharmacy Craiova, Craiova 200349, Romania. calinadaniela@gmail.com."}], "LastName": "Calina", "ForeName": "Daniela", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Parasitology, Zabol University of Medical Sciences, Zabol 61663-335, Iran. mehdi_sharifirad@yahoo.com."}], "LastName": "Sharifi-Rad", "ForeName": "Mehdi", "Initials": "M"}, {"Identifier": ["0000-0003-0378-8887"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Technology, Avicenna Tajik State Medical University, Rudaki 139, Dushanbe 734003, Tajikistan. shfarukh@mail.ru."}], "LastName": "Sharopov", "ForeName": "Farukh", "Initials": "F"}, {"Identifier": ["0000-0002-5934-5201"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal. ncmartins@med.up.pt."}, {"Identifier": [], "Affiliation": "Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal. ncmartins@med.up.pt."}], "LastName": "Martins", "ForeName": "Nat\u00e1lia", "Initials": "N"}, {"Identifier": ["0000-0002-7301-8151"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zabol Medicinal Plants Research Center, Zabol University of Medical Sciences, Zabol 61615-585, Iran. javad.sharifirad@gmail.com."}, {"Identifier": [], "Affiliation": "Department of Chemistry, Richardson College for the Environmental Science Complex, The University of Winnipeg, Winnipeg, MB R3B 2G3, Canada. javad.sharifirad@gmail.com."}], "LastName": "Sharifi-Rad", "ForeName": "Javad", "Initials": "J"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Biomolecules", "NlmUniqueID": "101596414", "ISSNLinking": "2218-273X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Alkaloids"}, {"RegistryNumber": "0", "NameOfSubstance": "Analgesics"}, {"RegistryNumber": "0", "NameOfSubstance": "Bridged Bicyclo Compounds, Heterocyclic"}, {"RegistryNumber": "0", "NameOfSubstance": "Isoxazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyridines"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrrolidines"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Nicotinic"}, {"RegistryNumber": "147402-53-7", "NameOfSubstance": "3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole"}, {"RegistryNumber": "9035-51-2", "NameOfSubstance": "Cytochrome P-450 Enzyme System"}, {"RegistryNumber": "M6K314F1XX", "NameOfSubstance": "epibatidine"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "pharmacokinetics", "therapeutic use"], "DescriptorName": "Alkaloids"}, {"QualifierName": ["chemistry", "pharmacokinetics", "therapeutic use"], "DescriptorName": "Analgesics"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Attention Deficit Disorder with Hyperactivity"}, {"QualifierName": ["chemistry", "pharmacokinetics", "therapeutic use"], "DescriptorName": "Bridged Bicyclo Compounds, Heterocyclic"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cytochrome P-450 Enzyme System"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Isoxazoles"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Neurodegenerative Diseases"}, {"QualifierName": ["chemistry", "pharmacokinetics", "therapeutic use"], "DescriptorName": "Pyridines"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Pyrrolidines"}, {"QualifierName": [], "DescriptorName": "Quantum Theory"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Receptors, Nicotinic"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Spande T.F., Garraffo H.M., Yeh H.J., Pu Q.L., Pannell L.K., Daly J.W. A new class of alkaloids from a dendrobatid poison frog: A structure for alkaloid 251f. J. Nat. Prod. 1992;55:707. doi: 10.1021/np50084a002.", "ArticleIdList": ["10.1021/np50084a002", "1522417"]}, {"Citation": "Spande T.F., Garraffo H.M., Edwards M.W., Yeh H.J.C., Pannell L., Daly J.W. Epibatidine: A novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. J. Am. Chem. Soc. 1992:3475. doi: 10.1021/ja00035a048.", "ArticleIdList": ["10.1021/ja00035a048"]}, {"Citation": "Posadas I., Lopez-Hernandez B., Cena V. Nicotinic receptors in neurodegeneration. Curr. Neuropharmacol. 2013;11:298\u2013314. doi: 10.2174/1570159X11311030005.", "ArticleIdList": ["10.2174/1570159X11311030005", "PMC3648781", "24179465"]}, {"Citation": "Boyle J. Molecular biology of the cell, by b. Alberts, a. Johnson, j. Lewis, m. Raff, k. Roberts, and p. Walter. Biochem. Mol. Biol. Educ. 2008;36:317\u2013318. doi: 10.1002/bmb.20192.", "ArticleIdList": ["10.1002/bmb.20192"]}, {"Citation": "Lloyd G.K., Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 2000;292:461\u2013467.", "ArticleIdList": ["10640281"]}, {"Citation": "Qian C., Li T., Shen T.Y., Libertine-Garahan L., Eckman J., Biftu T. Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol. 1993;250:13\u201314. doi: 10.1016/0014-2999(93)90043-H.", "ArticleIdList": ["10.1016/0014-2999(93)90043-H", "8112391"]}, {"Citation": "Sullivan J.P., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C.H., Adams P., Piattoni-Kaplan M., Buckley M.J. (+/\u2212)-epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 1994;271:624\u2013631.", "ArticleIdList": ["7965777"]}, {"Citation": "Thompson A.J., Metzger S., Lochner M., Ruepp M.-D. The binding orientation of epibatidine at \u03b17 nach receptors. Neuropharmacology. 2017;116:421\u2013428. doi: 10.1016/j.neuropharm.2017.01.008.", "ArticleIdList": ["10.1016/j.neuropharm.2017.01.008", "PMC5390772", "28089847"]}, {"Citation": "Baranowska U., Wi\u015bniewska R.J. The \u03b17-nach nicotinic receptor and its role in memory and selected diseases of the central nervous system. Postepy. Hig. Med. Dosw. 2017;30:633\u2013648. doi: 10.5604/01.3001.0010.3844.", "ArticleIdList": ["10.5604/01.3001.0010.3844", "28791958"]}, {"Citation": "Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Piattoni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., et al. Abt-594 [(r)-5-(2-azetidinylmethoxy)-2-chloropyridine]: A novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J. Pharmacol. Exp. Ther. 1998;285:777\u2013786.", "ArticleIdList": ["9580626"]}, {"Citation": "Shimizu T., Tanaka K., Hasegawa T., Yokotani K. Brain \u03b14\u03b22 nicotinic acetylcholine receptors are involved in the secretion of noradrenaline and adrenaline from adrenal medulla in rats. Eur. J. Pharmacol. 2011;654:241\u2013248. doi: 10.1016/j.ejphar.2010.12.034.", "ArticleIdList": ["10.1016/j.ejphar.2010.12.034", "21237150"]}, {"Citation": "Green B.T., Lee S.T., Keele J.W., Welch K.D., Cook D., Pfister J.A., Kem W.R. Complete inhibition of fetal movement in the day 40 pregnant goat model by the piperidine alkaloid anabasine but not related alkaloids. Toxicon. 2018;144:61\u201367. doi: 10.1016/j.toxicon.2018.02.007.", "ArticleIdList": ["10.1016/j.toxicon.2018.02.007", "29452148"]}, {"Citation": "Traynor J.R. Epibatidine and pain. Br. J. Anaesth. 1998;81:69\u201376. doi: 10.1093/bja/81.1.69.", "ArticleIdList": ["10.1093/bja/81.1.69", "9771274"]}, {"Citation": "London E.D., Scheffel U., Kimes A.S., Kellar K.J. In vivo labeling of nicotinic acetylcholine receptors in brain with [3h] epibatidine. Eur. J. Pharmacol. 1995;278:R1\u2013R2. doi: 10.1016/0014-2999(95)00178-N.", "ArticleIdList": ["10.1016/0014-2999(95)00178-N", "7664806"]}, {"Citation": "Javors M.A., Sanchez J.J., King T.S., Rohde A.R., Wilson S.G., Flores C.M. Extraction and quantification of epibatidine in plasma. J. Chromatogr. B Biomed. Sci. Appl. 2001;755:379\u2013382. doi: 10.1016/S0378-4347(01)00120-7.", "ArticleIdList": ["10.1016/S0378-4347(01)00120-7", "11393730"]}, {"Citation": "Shiraishi Y., Ogawa T., Suzuki T. Simultaneous quantification of batrachotoxin and epibatidine in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Legal. Med. 2017;25:1\u20135. doi: 10.1016/j.legalmed.2016.12.008.", "ArticleIdList": ["10.1016/j.legalmed.2016.12.008", "28457503"]}, {"Citation": "Watt A.P., Hitzel L., Morrison D., Locker K.L. Determination of the in vitro metabolism of (+)- and (\u2212)-epibatidine. J. Chromatogr. A. 2000;896:229\u2013238. doi: 10.1016/S0021-9673(00)00597-5.", "ArticleIdList": ["10.1016/S0021-9673(00)00597-5", "11093658"]}, {"Citation": "Heugebaert T.S.A., Van Overtveldt M., De Blieck A. Synthesis of 1-substituted epibatidine analogues and their in vitro and in vivo evaluation as a4\u00df2 nicotinic acetylcholine receptor ligands. RSC Adv. 2014;4:2226\u20132234. doi: 10.1039/C3RA44379E.", "ArticleIdList": ["10.1039/C3RA44379E"]}, {"Citation": "Patt M., Becker G.A., Grossmann U. Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (\u2212)-[18f]flubatine in humans. Nucl. Med. Biol. 2014;41:489\u2013494. doi: 10.1016/j.nucmedbio.2014.03.018.", "ArticleIdList": ["10.1016/j.nucmedbio.2014.03.018", "24768146"]}, {"Citation": "Ludwig F., Fischer S., Smits R. Exploring the metabolism of (+)-[18f] flubatine in vitro and in vivo: Lc-ms/ms aided identification of radiometabolites in a clinical pet study. Molecules. 2018;23:464. doi: 10.3390/molecules23020464.", "ArticleIdList": ["10.3390/molecules23020464", "PMC6017759", "29461507"]}, {"Citation": "Bunnelle W.H., MJ Dart M., Schrimpf M.R. Design of ligands for the nicotinic acetylcholine receptors: The quest for selectivity. Curr. Top. Med. Chem. 2004;4:299\u2013334. doi: 10.2174/1568026043451438.", "ArticleIdList": ["10.2174/1568026043451438", "14754449"]}, {"Citation": "Yogeeswari P., Sriram D., Bal T.R., Thirumurugan R. Epibatidine and its analogues as nicotinic acetylcholine receptor agonist: An update. Nat. Prod. Res. 2006;20:497\u2013505. doi: 10.1080/14786410600604583.", "ArticleIdList": ["10.1080/14786410600604583", "16644549"]}, {"Citation": "Carroll F.I. Epibatidine structure-activity relationships. Bioorganic Med. Chem. Lett. 2004;14:5713.", "ArticleIdList": ["15050621"]}, {"Citation": "Seerden J.G., Tulp M.T., Scheeren H.W., Kruse C.G. Synthesis and structure-activity data of some new epibatidine analogues. Bioorganic Med. Chem. Lett. 1998;6:2103\u20132110. doi: 10.1016/S0968-0896(98)00163-1.", "ArticleIdList": ["10.1016/S0968-0896(98)00163-1", "9881100"]}, {"Citation": "Badio B., Garraffo H.M., Plummer C.V., Padgett W.L., Daly J.W. Synthesis and nicotinic activity of epiboxidine: An isoxazole analogue of epibatidine. Eur. J. Pharmacol. 1997;321:189\u2013194. doi: 10.1016/S0014-2999(96)00939-9.", "ArticleIdList": ["10.1016/S0014-2999(96)00939-9", "9063687"]}, {"Citation": "Rizzi L., Dallanoce C., Matera C., Magrone P., Pucci L., Gotti C., Clementi F., De Amici M. Epiboxidine and novel-related analogues: A convenient synthetic approach and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes. Bioorg. Med. Chem. Lett. 2008;18:4651\u20134654. doi: 10.1016/j.bmcl.2008.07.016.", "ArticleIdList": ["10.1016/j.bmcl.2008.07.016", "18644719"]}, {"Citation": "Holladay M.W., Wasicak J.T., Lin N.-H., He Y., Ryther K.B., Bannon A.W., Buckley M.J., Kim D.J., Decker M.W., Anderson D.J. Identification and initial structure\u2014Activity relationships of (r)-5-(2-azetidinylmethoxy)-2-chloropyridine (abt-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1998;41:407\u2013412. doi: 10.1021/jm9706224.", "ArticleIdList": ["10.1021/jm9706224", "9484491"]}, {"Citation": "Meyer M.D., Anderson D.J., Campbell J.E., Carroll S., Marsh K.C., Rodrigues A.D., Decker M.W. Preclinical pharmacology of abt-594: A nicotinic acetylcholine receptor agonist for the treatment of pain. CNS Drug Rev. 2000;6:183\u2013194. doi: 10.1111/j.1527-3458.2000.tb00146.x.", "ArticleIdList": ["10.1111/j.1527-3458.2000.tb00146.x"]}, {"Citation": "Rowbotham M.C., Duan W.R., Thomas J., Nothaft W., Backonja M.-M. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of abt-594 in patients with diabetic peripheral neuropathic pain. Pain. 2009;146:245\u2013252. doi: 10.1016/j.pain.2009.06.013.", "ArticleIdList": ["10.1016/j.pain.2009.06.013", "19632048"]}, {"Citation": "Boyce S., Webb J.K., Shepheard S.L., Russell M.G., Hill R.G., Rupniak N.M. Analgesic and toxic effects of abt-594 resemble epibatidine and nicotine in rats. Pain. 2000;85:443\u2013450. doi: 10.1016/S0304-3959(99)00303-6.", "ArticleIdList": ["10.1016/S0304-3959(99)00303-6", "10781917"]}, {"Citation": "Bannon A.W., Decker M.W., Curzon P., Buckley M.J., Kim D.J., Radek R.J., Lynch J.K., Wasicak J.T., Lin N.-H., Arnold W.H. Abt-594 [(r)-5-(2-azetidinylmethoxy)-2-chloropyridine]: A novel, orally effective antinociceptive agent acting vianeuronal nicotinic acetylcholine receptors: Ii. In vivocharacterization. J. Pharmacol. Exp. Ther. 1998;285:787\u2013794.", "ArticleIdList": ["9580627"]}, {"Citation": "Munro G., Dyhr H., Grunnet M. Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist abt-594. Neuropharmacology. 2010;59:208\u2013217. doi: 10.1016/j.neuropharm.2010.05.010.", "ArticleIdList": ["10.1016/j.neuropharm.2010.05.010", "20562022"]}, {"Citation": "Taylor C.P. Mechanisms of action of gabapentin. Rev. Neurol. 1997;153(Suppl. 1):S39\u2013S45.", "ArticleIdList": ["9686247"]}, {"Citation": "Bitner R.S., Nikkel A.L., Curzon P., Arneric S.P., Bannon A.W., Decker M.W. Role of the nucleus raphe magnus in antinociception produced by abt-594: Immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. J. Neurosci. 1998;18:5426\u20135432. doi: 10.1523/JNEUROSCI.18-14-05426.1998.", "ArticleIdList": ["10.1523/JNEUROSCI.18-14-05426.1998", "PMC6793487", "9651224"]}, {"Citation": "Hayashi T., Katsuyama S., Orito T., Suzuki T., Sakurada S. Antinociceptive effect of tebanicline for various noxious stimuli-induced behaviours in mice. Neurosci. Lett. 2017;638:46\u201350. doi: 10.1016/j.neulet.2016.12.013.", "ArticleIdList": ["10.1016/j.neulet.2016.12.013", "27939354"]}, {"Citation": "Hone A.J., McIntosh J.M. Nicotinic acetylcholine receptors in neuropathic and inflammatory pain. FEBS Lett. 2018;592:1045\u20131062. doi: 10.1002/1873-3468.12884.", "ArticleIdList": ["10.1002/1873-3468.12884", "PMC5899685", "29030971"]}, {"Citation": "Sihver W., Nordberg A., L\u00e5ngstr\u00f6m B., Mukhin A.G., Koren A.O., Kimes A.S., London E.D. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav. Brain Res. 2000;113:143\u2013157. doi: 10.1016/S0166-4328(00)00209-6.", "ArticleIdList": ["10.1016/S0166-4328(00)00209-6", "10942041"]}, {"Citation": "Sihver W., L\u00e5ngstr\u00f6m B., Nordberg A. Ligands for in vivo imaging of nicotinic receptor subtypes in alzheimer brain. Acta Neurol. Scand. 2000;102:27\u201333. doi: 10.1034/j.1600-0404.2000.00304.x.", "ArticleIdList": ["10.1034/j.1600-0404.2000.00304.x", "11261802"]}, {"Citation": "Belluardo N., Mud\u00f2 G., Blum M., Cheng Q., Caniglia G., Dell\u2019Albani P., Fuxe K. The nicotinic acetylcholine receptor agonist (\u00b1)-epibatidine increases fgf-2 mrna and protein levels in the rat brain. Mol. Brain Res. 1999;74:98\u2013110. doi: 10.1016/S0169-328X(99)00266-1.", "ArticleIdList": ["10.1016/S0169-328X(99)00266-1", "10640680"]}, {"Citation": "Egea J., Rosa A.O., Cuadrado A., Garc\u00eda A.G., L\u00f3pez M.G. Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress. J. Neurochem. 2007;102:1842\u20131852. doi: 10.1111/j.1471-4159.2007.04665.x.", "ArticleIdList": ["10.1111/j.1471-4159.2007.04665.x", "17540012"]}, {"Citation": "Potter A., Corwin J., Lang J., Piasecki M., Lenox R., Newhouse P.A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) abt-418 in alzheimer\u2019s disease. Psychopharmacology. 1999;142:334\u2013342. doi: 10.1007/s002130050897.", "ArticleIdList": ["10.1007/s002130050897", "10229057"]}, {"Citation": "Wilens T.E., Biederman J., Spencer T.J., Bostic J., Prince J., Monuteaux M.C., Soriano J., Fine C., Abrams A., Rater M. A pilot controlled clinical trial of abt-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am. J. Psychiatry. 1999;156:1931\u20131937.", "ArticleIdList": ["10588407"]}, {"Citation": "Perry D.C., Kellar K.J. [3h] epibatidine labels nicotinic receptors in rat brain: An autoradiographic study. J. Pharmacol. Exp. Ther. 1995;275:1030\u20131034.", "ArticleIdList": ["7473129"]}]}], "History": [{"Year": "2018", "Month": "11", "Day": "20"}, {"Year": "2018", "Month": "12", "Day": "10"}, {"Year": "2018", "Month": "12", "Day": "17"}, {"Year": "2018", "Month": "12", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "12", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "6", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["30583611", "PMC6359223", "10.3390/biom9010006", "biom9010006"]}}]}